Key result
Passive immunization with specific anti-LDV monoclonal antibodies before or at the time of infection prevented the development of fatal paralytic disease in cyclophosphamide-treated mice.
Population
cyclophosphamide-treated, 6- to 7-month-old C58/M mice infected with a virulent strain of lactate…
Comparison
Passive immunization with polyclonal antibodies… vs Passive immunizations with other anti-LDV MAbs…
Design
Preclinical
Authors
Loading...
Antibody prophylaxis merits exploration in other neurotropic models; leaves open translation to human paralytic diseases.
Specific anti-LDV monoclonal antibodies can prevent fatal paralytic disease in mice by blocking the cytocidal infection of motor neurons.
Harty et al. (1990) studied Lactate dehydrogenase-elevating virus (LDV)-induced paralytic disease. Passive immunization with anti-LDV monoclonal antibodies vs. No protection / other MAbs was evaluated on Fatal paralytic disease. Passive immunization with specific anti-LDV monoclonal antibodies before or at the time of infection prevented the development of fatal paralytic disease in cyclophosphamide-treated mice.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: